Trial · NCT07596849
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849, Phase 3, Recruiting, argenx
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. Trials, record NCT07596849. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07596849
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
- NCT number
- NCT07596849
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 230 participants, estimated
- Lead sponsor
- argenx
- Conditions
- Graves Disease
- Interventions
- efgartigimod PH20 SC, Placebo PH20 SC
- First posted
- 2026-05-19
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A | up to 24 weeks (part A) | free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs |
| Secondary | Time to becoming euthyroid off ATDs in part A | Up to 24 weeks (part A) | ATDs: antithyroid drugs |
| Secondary | Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A | up to 24 weeks (part A) | MMI: methimazole (also known as thiamazole); CBZ carbimazole |
| Secondary | Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A | Up to 24 weeks (part A) | ULN : upper limit of normal; ATDs: antithyroid drugs |
| Secondary | Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A | up to 24 weeks (part A) | TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs |
| Secondary | Time to becoming euthyroid off ATDs and TRAb seronegative | up to 24 weeks (part A) + up to 135 weeks | ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies |
| Secondary | Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A) | up to 24 weeks | ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ carbimazole |
| Secondary | Time to becoming euthyroid | up to 24 weeks (part A) + up to 135 weeks | |
| Secondary | Time to having fT3 and fT4 levels within normal ranges among participants who had fT3 and/or fT4 more than the ULN at baseline (part A) | up to 24 weeks (part A) | ULN : upper limit of normal |
| Secondary | Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A) | up to 24 weeks (part A) | TSH: thyroid-stimulating hormone; LLN: lower limit of normal |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07596849
GET https://conductscience.org/api/trials/v1/NCT07596849/registered?page=2